279 related articles for article (PubMed ID: 25104330)
1. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.
Stoeck A; Lejnine S; Truong A; Pan L; Wang H; Zang C; Yuan J; Ware C; MacLean J; Garrett-Engele PW; Kluk M; Laskey J; Haines BB; Moskaluk C; Zawel L; Fawell S; Gilliland G; Zhang T; Kremer BE; Knoechel B; Bernstein BE; Pear WS; Liu XS; Aster JC; Sathyanarayanan S
Cancer Discov; 2014 Oct; 4(10):1154-67. PubMed ID: 25104330
[TBL] [Abstract][Full Text] [Related]
2. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
Wang K; Zhang Q; Li D; Ching K; Zhang C; Zheng X; Ozeck M; Shi S; Li X; Wang H; Rejto P; Christensen J; Olson P
Clin Cancer Res; 2015 Mar; 21(6):1487-96. PubMed ID: 25564152
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
[TBL] [Abstract][Full Text] [Related]
5. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.
Pandya K; Meeke K; Clementz AG; Rogowski A; Roberts J; Miele L; Albain KS; Osipo C
Br J Cancer; 2011 Sep; 105(6):796-806. PubMed ID: 21847123
[TBL] [Abstract][Full Text] [Related]
6. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
[TBL] [Abstract][Full Text] [Related]
7. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.
Azzam DJ; Zhao D; Sun J; Minn AJ; Ranganathan P; Drews-Elger K; Han X; Picon-Ruiz M; Gilbert CA; Wander SA; Capobianco AJ; El-Ashry D; Slingerland JM
EMBO Mol Med; 2013 Oct; 5(10):1502-22. PubMed ID: 23982961
[TBL] [Abstract][Full Text] [Related]
8. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
[TBL] [Abstract][Full Text] [Related]
9. GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.
Meng X; Matlawska-Wasowska K; Girodon F; Mazel T; Willman CL; Atlas S; Chen IM; Harvey RC; Hunger SP; Ness SA; Winter SS; Wilson BS
Leukemia; 2011 Jul; 25(7):1135-46. PubMed ID: 21494254
[TBL] [Abstract][Full Text] [Related]
10. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.
Mizuma M; Rasheed ZA; Yabuuchi S; Omura N; Campbell NR; de Wilde RF; De Oliveira E; Zhang Q; Puig O; Matsui W; Hidalgo M; Maitra A; Rajeshkumar NV
Mol Cancer Ther; 2012 Sep; 11(9):1999-2009. PubMed ID: 22752426
[TBL] [Abstract][Full Text] [Related]
11. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
Li ZL; Chen C; Yang Y; Wang C; Yang T; Yang X; Liu SC
Int J Clin Exp Pathol; 2015; 8(5):4378-87. PubMed ID: 26191129
[TBL] [Abstract][Full Text] [Related]
12. Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival.
Xie M; Wei S; Wu X; Li X; You Y; He C
Lung Cancer; 2018 Jul; 121():41-47. PubMed ID: 29858025
[TBL] [Abstract][Full Text] [Related]
13. Notch signaling promotes growth and invasion in uveal melanoma.
Asnaghi L; Ebrahimi KB; Schreck KC; Bar EE; Coonfield ML; Bell WR; Handa J; Merbs SL; Harbour JW; Eberhart CG
Clin Cancer Res; 2012 Feb; 18(3):654-65. PubMed ID: 22228632
[TBL] [Abstract][Full Text] [Related]
14. Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations.
Massé J; Truntzer C; Boidot R; Khalifa E; Pérot G; Velasco V; Mayeur L; Billerey-Larmonier C; Blanchard L; Charitansky H; Soubeyran I; Iggo R; Arnould L; MacGrogan G
Mod Pathol; 2020 Jun; 33(6):1041-1055. PubMed ID: 31857685
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
Cullion K; Draheim KM; Hermance N; Tammam J; Sharma VM; Ware C; Nikov G; Krishnamoorthy V; Majumder PK; Kelliher MA
Blood; 2009 Jun; 113(24):6172-81. PubMed ID: 19246562
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.
Tammam J; Ware C; Efferson C; O'Neil J; Rao S; Qu X; Gorenstein J; Angagaw M; Kim H; Kenific C; Kunii K; Leach KJ; Nikov G; Zhao J; Dai X; Hardwick J; Scott M; Winter C; Bristow L; Elbi C; Reilly JF; Look T; Draetta G; Van der Ploeg L; Kohl NE; Strack PR; Majumder PK
Br J Pharmacol; 2009 Nov; 158(5):1183-95. PubMed ID: 19775282
[TBL] [Abstract][Full Text] [Related]
17. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling.
Ferrarotto R; Mishra V; Herz E; Yaacov A; Solomon O; Rauch R; Mondshine A; Motin M; Leibovich-Rivkin T; Davis M; Kaye J; Weber CR; Shen L; Pearson AT; Rosenberg AJ; Chen X; Singh A; Aster JC; Agrawal N; Izumchenko E
Cell Death Dis; 2022 Aug; 13(8):678. PubMed ID: 35931701
[TBL] [Abstract][Full Text] [Related]
18. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.
Clementz AG; Rogowski A; Pandya K; Miele L; Osipo C
Breast Cancer Res; 2011 Jun; 13(3):R63. PubMed ID: 21679465
[TBL] [Abstract][Full Text] [Related]
19. Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model.
Masuda S; Kumano K; Suzuki T; Tomita T; Iwatsubo T; Natsugari H; Tojo A; Shibutani M; Mitsumori K; Hanazono Y; Ogawa S; Kurokawa M; Chiba S
Cancer Sci; 2009 Dec; 100(12):2444-50. PubMed ID: 19775286
[TBL] [Abstract][Full Text] [Related]
20. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
Front Immunol; 2019; 10():804. PubMed ID: 31105691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
